Clinical Trials Browser

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07082452 2025-07-24

SEVENAZA

Phase 3 Not yet recruiting

262 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT07052422 2025-07-04

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Phase 2/3 Not yet recruiting

160 enrolled

Other neoplasm

Older Patients

NCT06765928 2025-01-09

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

Phase 2 Not yet recruiting

73 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Phase 4 Not yet recruiting

172 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06470841 2024-08-22

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

Phase 2 Not yet recruiting

85 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2 Not yet recruiting

528 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05628623 2024-07-03

ERASE

Phase 2 Not yet recruiting

184 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06387420 2024-04-29

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Phase 1/2 Not yet recruiting

180 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06324994 2024-03-22

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Phase 2 Not yet recruiting

10 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT04790045 2023-10-03

LymBIO

Phase 4 Not yet recruiting

30 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05054465 2021-09-23

ITALLI001

Phase 1/2 Not yet recruiting

48 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

VAH vs VA in Newly Diagnosed Elderly AML

A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

VHAG

Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

VAG-3+7-G

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia

VENP-A-QUI

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

GAVEL

FIT-AML

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

MAVRiC

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

TAGVEN

HEM-iSMART E

SEVENAZA

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

ERASE

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

LymBIO

ITALLI001